AnaptysBio Reports Q3 and Transitional FY 2026 Financial Results

What Happened

• On September 21, 2026, AnaptysBio, Inc. announced its financial results for the three months and the transitional fiscal year ended June 30, 2026 via a press release. The company filed a Current Report on Form 8‑K (Item 2.02) attaching that press release as Exhibit 99.1. The filing was signed by Christopher M. Murphy, Chief Financial Officer.

Key Details

• Filing date: September 21, 2026 (Form 8‑K reporting Item 2.02: Results of Operations and Financial Condition).
• Reporting period: three months and transitional fiscal year ended June 30, 2026.
• Exhibit: Press release attached as Exhibit 99.1 to the 8‑K.
• Filing also includes Exhibit 104 (cover page XBRL tags) as noted in the exhibits table.

Why It Matters

• This 8‑K signals that AnaptysBio has published its latest quarterly/transitional fiscal‑year earnings and financial condition; investors should read the attached press release (Exhibit 99.1) for revenue, net income/loss, cash position, and any management commentary or guidance.
• Because the 8‑K itself only references the press release, reviewing the full exhibit or the company’s earnings presentation will provide the concrete numbers and context needed to assess near‑term performance and any impact on valuation.